Patent Application
20240409608
The contents of the electronic sequence listing (10040-002PCT_sequence listing_ST26.xml; size 79 KB; creation date Aug. 23, 2022) is herein incorporated by reference in its entirety.
The present invention relates generally to combination therapies, and more specifically to combinations of immunogenic fusion proteins with immune checkpoint antibodies for eliciting T cell-mediated immune responses against tumors and infectious diseases.
The adaptive immune system includes both humoral and cell-mediated immunity, both of which contribute to destroy invading pathogens. B- and T-lymphocytes are responsible for antibody and cell-mediated immune responses, respectively. Adaptive immunity against cancer or pathogens leads to enhanced immune responses to future encounters. Several adaptive immunity therapy strategies have been evaluated in the clinical settings. There is, however, still a need for developing new immunotherapies, e.g., combination immunotherapies, to combat cancer and infectious diseases caused by pathogens.
In one aspect, the invention relates to a combination or pharmaceutical composition comprising: (a) an immune checkpoint antibody capable of activating T cell; and (b) a fusion protein, wherein the fusion protein comprises: (i) a CD40-binding domain; (ii) an antigen; (iii) a translocation domain, located between the CD40-binding domain and the antigen; and (iv) a furin and/or cathepsin L cleavage site, located between the CD40-binding domain and the translocation domain.
In another aspect, the invention relates to a combination or a pharmaceutical composition for use in eliciting an antigen-specific cell-mediated immune response, treating a tumor or a disease caused by a pathogen in a subject in need thereof.
Professional APCs and non-professional APCs use an MHC class I molecule to display endogenous peptides on the cell membrane. These peptides originate within the cell itself, in contrast to the exogenous antigen displayed by professional APCs using MHC class II molecules. Cytotoxic T cells are able to interact with antigens presented by the MHC class I molecule.
CD40 is a costimulatory protein expressed on antigen-presenting cells (e.g., dendritic cells, macrophages and B cells). The binding of CD40L to CD40 activates antigen-presenting cells and induces a variety of downstream effects. CD40 is a drug target for cancer immunotherapy.
The term “a CD40-binding domain” refers to a protein that can recognize and binds to CD40. A CD40-binding domain may be selected from one of the following: “CD40 ligand (CD40L) or a functional fragment thereof”, “an anti-CD40 antibody or a functional fragment thereof.”
The terms “CD40L”, “CD40 ligand” and “CD154” are interchangeable. CD40L binds to CD40 (protein) on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. CD40L plays a central role in co-stimulation and regulation of the immune response via T cell priming and activation of CD40-expressing immune cells. U.S. Pat. No. 5,962,406 discloses the nucleotide and amino acid sequence of CD40L.
The terms “anti-CD40 antibody” and “CD40-specific antibody” are interchangeable.
When the term “consist substantially of” or “consisting substantially of” is used in describing an amino acid sequence of a polypeptide, it means that the polypeptide may or may not have a starting amino acid “M” (translated from a start codon AUG) at N-terminal as a part of the polypeptide, depending on protein translation requirements. For example, when the antigen HPV 18 E7 protein (SEQ ID NO: 39) fused to another polypeptide (e.g., another antigen), the starting amino acid “M” could be omitted or kept.
As used herein, “a translocation domain” is a polypeptide having biological activity in translocating an antigen within a fusion protein across an endosomal membrane into the cytosol of the CD40-expressing cell. The translocation domain guides or facilitates the antigen toward class I major histocompatibility complex (MHC-1) pathway (i.e., a cytotoxic T cell pathway) for antigen presentation.
The term “a Pseudomonas Exotoxin A (PE) translocation peptide (TPE)” refers to a PE domain II peptide or a functional fragment thereof that has the biological activity in translocation.
The term “a Shiga toxin (Stx) translocation peptide (TStx)” refers to a Stx translocating domain or a functional fragment thereof that has the biological activity in translocation.
The terms “furin and/or cathepsin L” or “furin/cathepsin L” are interchangeable. A furin and/or cathepsin L cleavage site refers to a protease (furin and/or cathepsin L) sensitive site. It is a short peptide sequence that can be cleaved by furin or cathepsin L, or by both furin and cathepsin L. It may be a peptide linker comprising said cleavage site that is introduced into the fusion protein, or an intrinsic protease cleavage site present in the translocation domain of the fusion protein.
The terms “antigen” and “immunogen” are interchangeable. An antigen refers to an antigenic protein, which may be a tumor antigen (an antigen from a cancer or an antigen associated with a cancer), or an antigen of a pathogen (an antigen from a pathogen).
The terms “tumor” and “cancer” are interchangeable.
The terms “an antigen of a cancer cell” and “a tumor antigen” are interchangeable.
The term “a tumor antigen” refers to a tumor-specific antigen and/or a tumor-associated antigen. A tumor-associated antigen may be a protein or polypeptide expressed on the surface of a tumor cell.
Cluster of Differentiation 28 (CD28) is a T-cell-specific surface glycoprotein. A CD28 receptor is stimulated during the contact of T cells with antigen-presenting cells. Its function is involved in T-cell activation, the induction of cell proliferation and cytokine production and promotion of T-cell survival.
The term “an effective amount” refers to the amount of an active fusion protein that is required to confer a therapeutic effect on the treated subject. Effective doses will vary, as recognized by those skilled in the art, depending on rout of administration, excipient usage, and the possibility of co-usage with other therapeutic treatment.
The term “treating”, or “treatment” refers to administration of an effective amount of the fusion protein to a subject in need thereof, who has cancer or infection, or a symptom or predisposition toward such a disease, with the purpose of cure, alleviate, relieve, remedy, ameliorate, or prevent the disease, the symptoms of it, or the predisposition towards it. Such a subject can be identified by a health care professional based on results from any suitable diagnostic method.
The term “combination” or “combination therapy” or “combination immunotherapy” refers to a combination of one or more active drug substances that have a therapeutic effect. A combination may be provided in a single pharmaceutical composition so that a first active drug substance (e.g., an immune checkpoint antibody) and a second active drug substance (e.g., a fusion protein of the invention) can be administered together. In alternative embodiments, a combination may be provided using more than one pharmaceutical composition. In such embodiments, the first active drug substance may be provided in a first pharmaceutical composition and the second active drug substance may be provided in a second pharmaceutical composition so that the two drug substances can be administered separately such as, for example, at different times, by different routes of administration, and the like. Thus, it also may be possible to provide the two active drug substances in different dosing regimens.
By “0 to 12 repeats” or “2 to 6 repeats”, it means that all integer unit amounts within the range “0 to 12” or “2 to 6” are specifically disclosed as part of the invention. Thus, 0, 1, 2, 3, 4, . . . 10, 11 and 12″ or “2, 3, 4, 5 and 6” unit amounts are included as embodiments of this invention.
In one aspect, the invention relates to a combination comprising: (a) an immune checkpoint antibody capable of activating a T cell; and (b) a fusion protein, comprising: (i) a CD40-binding domain; (ii) an antigen; (iii) a translocation domain, located between the CD40-binding domain and the antigen; and (iv) a furin and/or cathepsin L cleavage site, located between the CD40-binding domain and the translocation domain.
An immune checkpoint antibody is able to restore or enhance T cell activation via (1) blocking an inhibitory immune checkpoint or (2) activating a stimulatory immune checkpoint.
In one embodiment, the immune checkpoint antibody is (1) an antagonist antibody capable of targeting an inhibitory immune checkpoint, (2) an agonist antibody capable of targeting a stimulatory immune checkpoint, or (3) a bispecific antibody capable of targeting two immune checkpoints. The inhibitory immune checkpoints include, but not limited to, PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD96, CD122R, TIM3, VISTA, CEACAMI, SIGLEC-7, SIGLEC-9, SIGLEC-15, KIRi, CD200R, BTLA, and ILT2. The stimulatory immune checkpoints include, but not limited to, CD137 (4-1BB), OX40, GITR, ICOS, CD27, CD28, CD40, KIRs, CD226 and CD244.
In some embodiments, the immune checkpoint antibody is an antagonist antibody capable of targeting PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD96, CD122R, TIM3, VISTA, CEACAMI, SIGLEC-7, SIGLEC-9, SIGLEC-15, KIRi, CD200R, BTLA, and ILT2. In some embodiments, the immune checkpoint antibody is an agonist antibody capable of targeting CD137 (4-1BB), OX40, GITR, ICOS, CD27, CD28, CD40, KIRs, CD226 and CD244.
In one embodiment, the immune checkpoint antibody is an anti-PD-1 antibody, e.g., Keytruda® (pembrolizumab), Opdivo® (nivolumab), Libtayo® (cemiplimab), or Jemperli® (dostarlimab). In one embodiment, the immune checkpoint antibody is an anti-PD-L1 antibody, e.g., Tecentriq® (atezolizumab), Imfinzi® (durvalumab), or Bavencio (avelumab). In one embodiment, the immune checkpoint antibody is an anti-CTLA-4 antibody, e.g., Yervoy® (ipilimumab). In one embodiment, the immune checkpoint antibody is an anti-LAG3 antibody, e.g., Relatlimab (BMS-986016). In one embodiment, the immune checkpoint antibody is an anti-TIGIT antibody, e.g., tiragolumab. In one embodiment, the immune checkpoint antibody is an anti-CD137 antibody, e.g., LVGN6051 or Urelumab (BMS-663513). In one embodiment, the immune checkpoint antibody is an anti-OX40 antibody, e.g., PF-04518600, BMS-986178, or MEDI6469. In one embodiment, the immune checkpoint antibody is a CD137/PD-L1 bispecific antibody, e.g., FS222. In one embodiment, the immune checkpoint antibody is a CD137/OX40 bispecific antibody, e.g., FS120.
In some embodiments, the immune checkpoint antibody comprises a fully antibody, a single chain variable fragment (scFv), a diabody (dscFv), a triabody, a tetrabody, a bispecific-scFv, a scFv-Fc, a scFc-CH3, a single chain antigen-binding fragment (scFab), an antigen-binding fragment (Fab), Fab2, a minibody, or an antibody analogue comprising one or more CDRs.
The fusion proteins of the invention can elicit an antigen-specific T cell immune response via MHC class I antigen presentation pathway. They share a common mechanism of action. Using 18sCD40L-TPE-E7 as an example, the mechanism of action is as follows: (1) 18sCD40L-TPE-E7 binds to a CD40-expressing cell (e.g., dendritic cell or macrophage) and is internalized via a CD40-mediated endocytosis; (2) 18sCD40L-TPE-E7 is cleaved by furin protease and/or cathepsin L protease within the endosome so as to remove the 18sCD40L fragment away from the TPE-E7 fragment; (3) the TPE-E7 fragment is translocated across the endosomal membrane of the endosome into the cytosol; (4) the TPE-E7 fragment is digested by cytosol proteasome to generate small E7 antigens with epitopes; (5) the E7 antigens are delivered via MHC class I pathway for antigen presentation; and (6) a CD8+ T cell specific immune response is induced or enhanced by T-cell recognizing these presented antigens.
The same mechanism of action is applicable to E7-TStx-18sCD40L, in which furin and/or cathepsin L protease cleavage would remove E7-TStx fragment away from 18sCD40L fragment. Thus, E7-TStx fragment would be translocated across the endosomal membrane of the endosome, enter the cytosol, digested by cytosol proteasome to generate small E7 antigens with epitopes; the small E7 antigens would be delivered via MHC class I pathway for antigen presentation; and a CD8+ T cell specific immune response would be induced or enhanced by T-cell recognizing these presented antigens.
No furin and/or cathepsin L cleavage site is present between the antigen and the translocation domain in the fusion protein of the invention. The presence of a furin and/or cathepsin L cleavage site and its location in the fusion protein of the invention permits removal of CD40-binding domain from the fusion protein after the furin and/or cathepsin L cleavage.
In some embodiments, the furin and/or cathepsin L cleavage site comprises or consists of 4-20 amino acids, preferred 4-10 amino acids, and more preferred 4-6 amino acids. In some embodiments, the furin and/or cathepsin L cleavage site comprises, consists of, or is, SEQ ID NO: 1 or 2.
The fusion protein of the invention may further comprise a peptide linker present between the CD40-binding domain and the translocation domain, wherein the furin and/or cathepsin L cleavage site is present in said peptide linker. The peptide linker may comprise (a) a rigid linker (EAAAAK)n or (SEQ ID NO: 38)n; and (b) a cleavable linker comprising a furin and/or cathepsin L cleavage site, wherein n is an integer from 0-12, preferably from 2-6, more preferably from 3-4, and said furin and/or cathepsin L cleavage site comprises SEQ ID NO: 1 or 2. In one embodiment, the peptide linker comprises (EAAAAK)3 and RX1RX2X3R (SEQ ID NO: 2; wherein X1 is A, X2 is Y, X3 is K). In another embodiment, the peptide linker comprises RX1X2R (SEQ ID NO: 1; wherein X1 is V, X2 is A) and (EAAAAK)3.
The translocation domain and the antigen are located within the fusion protein in such an orientation and/or relation that permits the translocating domain to translocate the antigen across the membrane of the endosome and enter the cytosol, and then facilitate the antigen toward MHC class I pathway for antigen presentation in the CD40-expressing cell.
The translocation domain may be derived from a Pseudomonas Exotoxin A (PE), or from a Shiga toxin (Stx). In one embodiment, the translocation domain comprises, or is, a Pseudomonas Exotoxin A (PE) translocation peptide (TPE), with the proviso that the CD40-binding domain is located at the N-terminal of the fusion protein. In another embodiment, the translocation domain comprises, or is, a Shiga toxin (Stx) translocation peptide (TStx), with the proviso that the antigen is located at the N-terminal of the fusion protein.
In one embodiment, a fusion protein of the invention sequentially (from N-terminal to C-terminal) comprises: (a) a CD40-binding domain; (b) a furin and/or cathepsin L cleavage site; (c) a translocation domain comprising a PE translocation peptide (TPE); and (d) an antigen.
In another embodiment, a fusion protein of the invention sequentially (from N-terminal to C-terminal) comprises: (a) a CD40-binding domain; (b) a peptide linker comprising a furin and/or cathepsin L cleavage site; (c) a translocation domain comprising a PE translocation peptide (TPE); and (d) an antigen.
In another embodiment, a fusion protein of the invention sequentially (from N-terminal to C-terminal) comprises: (a) an antigen; (b) a translocation domain comprising a Stx translocation peptide (TStx); (c) a furin and/or cathepsin L cleavage site; and (d) a CD40-binding domain.
In another embodiment, a fusion protein of the invention sequentially (from N-terminal to C-terminal) comprises: (a) an antigen; (b) a translocation domain comprising a Stx translocation peptide (TStx); (c) a peptide linker comprising a furin and/or cathepsin L cleavage site; and (d) a CD40-binding domain.
The TPE or TStx is a functional moiety having a biological activity in translocation. The furin and/or cathepsin L cleavage site may be one selected from SEQ ID NO: 1, SEQ ID NO: 2, or an intrinsic furin cleavage site within, or derived from, PE or Stx.
In one embodiment, a PE translocation peptide (TPE) is domain II (amino acid residues 253-364; SEQ ID NO: 9) of Pseudomonas Exotoxin A protein (full-length PE, SEQ ID NO: 4) or a functional moiety thereof.
In some embodiments, the PE translocation peptide (TPE) consists of 26-112 amino acid residues in length. The PE translocation peptide (TPE) comprises a minimal functional fragment of GWEQLEQCGYPVQRLVALYLAARLSW (SEQ ID NO: 5).
In one embodiment, a PE translocation peptide (TPE) comprises an amino acid sequence that is at least 95%, 97% or 99% identical to SEQ ID NO: 5, 6, 7, 8 or 9. In another embodiment, a TPE comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5, 6, 7, 8 and 9. In another embodiment, a TPE is PE280-305 (SEQ ID NO: 5), PE280-313 (SEQ ID NO: NO: 6), PE268-313 (SEQ ID NO: NO: 7), PE253-313 (SEQ ID NO: 8), or PE253-364 (SEQ ID NO: 9; full-length PE domain II).
In one embodiment, a Stx translocation peptide (TStx) is a functional fragment of Shiga toxin (Stx) subunit A (SEQ ID NO: 10) or Shiga-like toxin I (Slt-I) subunit A (SEQ ID NO: 11). A Stx translocation peptide has translocation function but no cytotoxic effect of subunit A. Sequence identify between Shiga toxin (Stx) subunit A and Slt-I subunit A is 99% and the two proteins has only one amino acid difference.
In some embodiments, the Stx translocation peptide (TStx) consists of 8-84 amino acid residues in length. The Stx translocation peptide (TStx) comprises a minimal functional fragment of LNCHHHAS (SEQ ID NO: 12).
In one embodiment, a Stx translocation peptide (TStk) comprises an amino acid sequence that is at least 95%, 97% or 99% identical to SEQ ID NO: 12, 13, 14, 15 or 16. In another embodiment, a TStx comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 14, 15 and 16. In another embodiment, a TStx is Stx240-247 (SEQ ID NO: 12), Stx240-251 (SEQ ID NO: 13), Stx211-247 (SEQ ID NO: 14), Stx211-251 (SEQ ID NO: 15) or Stx168-251 (SEQ ID NO: 16) of Stx subunit A.
A CD40-binding domain is a polypeptide having a biological activity in binding to CD40 protein on a CD40-expressing cell. A CD40-binding domain permits a fusion protein of the invention to bind to a CD40 receptor on a CD40-expressing cell (e.g., dendritic cell or macrophage). A CD40-binding domain may be one selected from the group consisting of (i) a CD40 ligand (CD40L) or a functional fragment thereof; and (ii) a CD40-specific antibody or a functional fragment thereof.
In one embodiment, a functional fragment of CD40L is a truncated CD40L having said biological activity, substantially lacking transmembrane and cytoplasmic regions of the full-length CD40L1-261 protein (SEQ ID NO: 17).
In another embodiment, the CD40L or a functional fragment thereof consists of 154-261 amino acid residues in length. In some embodiments, the CD40L comprises a minimal functional fragment of SEQ ID NO: 19. In a particular embodiment, the CD40L or a functional fragment thereof consists of 154-261 amino acid residues in length and said CD40L comprises a minimal functional fragment of SEQ ID NO: 19.
In one embodiment, a CD40L comprises an amino acid sequence that is at least 95%, 97% or 99% identical to SEQ ID NO: 17, 18 or 19. In another embodiment, a CD40L is selected from the group consisting of CD40L1-261 (SEQ ID NO: 17), CD40L47-261 (SEQ ID NO: 18) and CD40L108-261 (SEQ ID NO: 19).
In another embodiment, a CD40-binding domain is a CD40-specific antibody (or anti-CD40 antibody). A CD40-specific antibody is an antibody specifically recognizing and binding to CD 40 protein. A CD40-specific antibody can bind to CD40 protein on a CD40-expressing cell.
In one embodiment, the CD40-specific antibody comprises a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein the VH comprises the amino acid sequence of SEQ ID NO: 22; and the VL comprises the amino acid sequence of SEQ ID NO: 23.
In another embodiment, the CD40-specific antibody is selected from the group consisting of a single chain variable fragment (scFv), a diabody (dscFv), a triabody, a tetrabody, a bispecific-scFv, a scFv-Fc, a scFc-CH3, a single chain antigen-binding fragment (scFab), an antigen-binding fragment (Fab), Fab2, a minibody and a fully antibody.
In another embodiment, a CD40-binding domain is a CD40-specific scFv (anti-CD40 scFv) comprising a heavy chain variable domain (VH), a light chain variable domain (VL) and a flexible linker (L) connecting the VH and the VL.
In one embodiment, a CD40-specific scFv comprises SEQ ID NO: 20 or 21.
In another embodiment, the CD40-binding domain according to the invention is (i) a CD40-specific antibody or a binding fragment thereof, or (ii) a CD40-specific single chain variable fragment (scFv) or a binding fragment thereof; said CD40-specific antibody or said CD40-specific scFv comprising a VH and a VL wherein: (a) the VH comprises SEQ ID NO: 22; and (b) the VL comprises SEQ ID NO: 23.
In another embodiment, the CD40-specific antibody or CD40-specific scFv comprises a VH and a VL, the VH comprising VH CDR1, VH CDR2 and VH CDR3; and the VL comprising VL CDR1, VL CDR2 and VL CDR3, wherein: (i) the VH CDR1, VH CDR2 and VH CDR3 comprises SEQ ID NO: 24, 25 and 26, respectively; and (ii) the VL CDR1, VL CDR2 and VL CDR3 comprises SEQ ID NO: 27, 28 and 29, respectively.
In another embodiment, the CD40-binding domain is a CD40-specific scFv comprising a VH and a VL, wherein: (a) the VH comprises SEQ ID NO: 22; and (b) the VL comprises SEQ ID NO: 23.
In another embodiment, the fusion protein of the invention further comprises an endoplasmic reticulum (ER) retention sequence located at the C-terminal of the antigen, with the proviso that the translocation domain comprises a PE translocation peptide (TPE). As used herein, the ER retention sequence may comprise SEQ ID NO: 30, 31, 32, 33 or 34. In some embodiments, the ER retention is SEQ ID NO: 30.
In another embodiment, the fusion protein of the invention further comprises a CD28-activating peptide located between the CD40-binding domain and the furin and/or cathepsin L cleavage site.
In some embodiments, the CD28-activating peptide consists of 28-53 amino acid residues in length. In some embodiments, the CD28-activating peptide comprises a minimal functional fragment of SEQ ID NO: 35. In a particular embodiment, the CD28-activating peptide consists of 28-53 amino acid residues in length and said CD28-activating peptide comprises a minimal functional fragment of SEQ ID NO: 35.
In another embodiment, the CD28-activating peptide comprises an amino acid sequence that is at least 95%, 97% or 99% identical to SEQ ID NO: 35, 36 or 37. In another embodiment, the CD28-activating peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 35, 36 and 37. In another embodiment, the CD28-activating peptide is SEQ ID NO: 35, 36 or 37.
An antigen in the fusion protein of the invention is an antigen of a pathogen or a tumor antigen.
The pathogen may be selected from the group consisting of Human Papillomavirus (HPV), Human Immunodeficiency Virus-1 (HIV-1), Influenza Virus, Dengue Virus, Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), Hepatitis E Virus (HEV), Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-COV), Severe Acute Respiratory Syndrome Coronavirus2 (SARS-COV2), Middle East Respiratory Syndrome Coronavirus (MERS-Cov), Epstein-Barr Virus (EBV), Zika Virus, Rabies Virus, Variola Virus, Chikungunya Virus, West Nile Virus, Poliovirus, Measles Virus, Rubella Virus, Hantavirus, Japanese Encephalitis Virus, Coxsackievirus, Echovirus, Enterovirus, Mumps Virus, Varicella-Zoster Virus (VZV), Cercopithecine Herpesvirus-1 (CHV-1), Yellow Fever Virus (YFV), Rift Valley Fever Virus, Lassa Virus, Marburg Virus, Ebolavirus, Norovirus, Rotavirus, Adenovirus, Sapovirus, Astrovirus, Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), African Swine Fever Virus (ASFV), Classical Swine Fever Virus (CSFV), Porcine Circovirus 2 (PCV2), Foot-and-Mouth Disease Virus (FMDV), Porcine Epidemic Diarrhea Virus (PEDV), Swine Vesicular Disease Virus (SVDV), Pseudorabies Virus (PRV), Transmissible Gastroenteritis Virus (TGEV), Newcastle Disease Virus (NDV), Infectious Bronchitis Virus (IBV), Infectious Bursal Disease Virus (IBDV), Mycoplasma hyopneumoniae, Rickettsia prowazekii, Rickettsia typhi, Orientia tsutsugamushi, Borrelia burgdorferi, Yersinia pestis, Plasmodium vivax, Plasmodium malariae, Plasmodium falciparum, Plasmodium ovale, Bacillus anthracis, Clostridium Difficile, Clostridium Botulinum, Corynebacterium diphtheriae, Salmonella enterica serovar Typhi, Salmonella enterica scrovar Paratyphi A, Shiga toxin-producing E. coli (STEC), Shigella dysenteriae, Shigella flexneri, Shigella boydii, Shigella sonnei, Entamoeba histolytica, Vibrio cholerae, Mycobacterium tuberculosis, Neisseria meningitidis, Bordetella pertusis, Haemophilus influenzae type B (HiB), Clostridium tetani, Listeria monocytogenes and Streptococcus pneumoniae.
In another embodiment, the pathogen is selected from the group consisting of HPV, HIV-1, Influenza Virus, Dengue Virus, HAV, HBV, HCV, SARS-COV, SARS-COV-2. More particularly, the pathogen is selected from the group consisting of HPV, HBV, HCV and SARS-COV2.
In another embodiment, the antigen is a pathogenic antigen selected or derived from the group consisting of HPV 16 E7 protein, HPV18 E7 protein, HBV X protein (HBx), HBV preS1 protein, HCV core protein (HCVcore), SARS-COV2 spike protein (CoV2S), SARS-COV2 envelope protein, SARS-CoV2 membrane protein and SARS-COV2 nucleocapsid protein.
In another embodiment, said antigen comprises at least one epitope for inducing a desired immune response, preferably containing 1 to 50 epitopes, more preferably containing 1 to 20 epitopes.
In another embodiment, the antigen is a pathogenic antigen comprising or consisting substantially of an amino acid sequence that is at least 70%, 80%, 90%, 95% or 99% identical to SEQ ID NO: 38, 39, 40, 41, 42 or 43.
In another embodiment, the antigen is a pathogenic antigen comprising or consisting substantially of an amino acid sequence that is at least 80% identical to SEQ ID NO: 38, 39, 40, 41, 42 or 43.
In another embodiment, the antigen comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 38, 39, 40, 41, 42 and 43.
In another embodiment, the antigen is a tumor antigen. A tumor antigen is a tumor-associated antigen (TAA) or a tumor-specific antigen (TSA).
In one embodiment, the tumor or cancer is selected from the group consisting of breast cancer, colon cancer, rectal cancer, bladder cancer, endometrial cancer, kidney cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), small cell lung cancer, non-small cell lung cancer (NSCLC), melanoma, ovarian cancer, cervical cancer, pancreatic cancer, prostate cancer, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), non-Hodgkin's lymphoma, and thyroid cancer.
In another embodiment, a tumor-associated antigen is selected or derived from the group consisting of SSX2, MAGE-A3, NY-ESO-1, iLRP, WT12-281, RNF43, CEA-NE3, AFP, ALK, Anterior gradient 2 (AGR2), BAGE proteins, β-catenin, brc-abl, BRCA1, BORIS, CA9, carbonic anhydrase IX, caspase-8, CD40, CDK4, CEA, CTLA4, cyclin-B1, CYPIB1, EGFR, EGFRvIll, ErbB2/Her2, ErbB3, ErbB4, ETV6-AML, EphA2, Fra-1, FOLR1, GAGE proteins (e.g., GAGE-1, -2), GD2, GD3, GloboH, glypican-3, GM3, gp100, HLA/B-raf, HLA/k-ras, HLA/MAGE-A3, hTERT, LMP2, MAGE proteins (e.g., MAGE-1, -2, -3, -4, -6, and -12), MART-1, mesothelin, ML-IAP, Muc1, Muc16 (CA-125), MUM1, NA17, NY-BR1, NY-BR62, NY-BR85, NY-ES01, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PLAC1, PRLR, PRAME, PSMA (FOLH1), RAGE proteins, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, Steap-2, survivin, TAG-72, TGF-β, TMPRSS2, Tn, TRP-1, TRP-2, tyrosinase, and uroplakin-3.
In another embodiment, the antigen is a tumor-associated antigen selected or derived from the group consisting of SSX2, MAGE-A3, NY-ESO-1, iLRP, WT12-281, RNF43 and CEA-NE3.
In another embodiment, the antigen is a tumor-associated antigen comprising an amino acid sequence that is at least 70%, 80%, 90%, 95% or 99% identical to SEQ ID NO: 44, 45, 46, 47, 48, 49 or 50.
In another embodiment, the antigen is a tumor-associated antigen comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 44, 45, 46, 47, 48, 49 and 50.
An antigen may be a single antigen or an antigenic fragment thereof, or a fusion antigen comprising at least two antigenic polypeptides fused together. For example, an antigen may be a single antigen of HPV16 E7 protein or a fusion antigen comprising HPV16 E7 and HPV18 E7 proteins. A fusion antigen may or may not have a linker connecting different antigenic polypeptides.
In another embodiment, the antigen is a fusion antigen having at least one linker connecting different antigens.
In another embodiment, the antigen is a fusion antigen having a rigid linker, (EAAAAK)n, connecting different antigens, wherein n is an integer from 0-12, preferably from 2-6, more preferably from 3-4. In other words, the rigid linker comprises 0 to 12 repeats, 2 to 6 repeats or 3-4 repeats of the sequence EAAAAK (SEQ ID NO: 56).
In another embodiment, the fusion protein of the invention further comprises a rigid linker between the CD40-binding domain and the furin and/or cathepsin L cleavage site. The rigid linker may be a peptide liner comprising 0 to 12 repeats of the amino acid sequence EAAAAK (SEQ ID NO: 56).
The rigid linker may be (EAAAAK)n, or (SEQ ID NO: 56)n, wherein n is an integer from 0-12, preferably from 2-6, more preferably from 3-4.
In another embodiment, the rigid linker comprises 2 to 6 repeats or 3-4 repeats of SEQ ID NO: 56.
In another embodiment, the fusion protein of the invention comprises, or consists substantially of, an amino acid sequence that is at least 90%, 95% or 99% identical to SEQ ID NO: 51, 52, 53, 54 or 55.
Further in another embodiment, the fusion protein of the invention comprises, or consists substantially of, an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 52, 53, 54 and 55.
The invention also relates to a pharmaceutical composition comprising: (a) a combination according to the invention; and (b) a pharmaceutical acceptable carrier or adjuvant.
The term “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives, isotonic agents, absorption delaying agents, salts, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except in so far as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
Suitable adjuvants include, but not limited to, a saponin-based adjuvant and a Toll-like receptor (TLR) agonist adjuvant. The saponin-based adjuvant may be GPI-0100, Quil A or QS-21. The TLR agonist adjuvant may be selected from a TLR3, TLR4 or TLR9 agonist, e.g., Poly I: C (TLR3 agonist), monophosphoryl lipid A (MPL; TLR4 agonist) or CpG oligonucleotide (TLR9 agonist). The CpG oligonucleotide adjuvant includes, but not limited to, class A CpG (i.e., CpG1585, CpG2216 or CpG2336), class B CpG (i.e., CpG1668, CpG1826, CpG2006, CpG2007, CpG BW006 or CpG D-SL01) and class C CpG (i.e., CpG2395, CpG M362 or CpG D-SL03). In addition, another adjuvant CpG1018 (Dynavax) is also considerable. In some embodiments, the adjuvant is a CpG oligonucleotide.
The pharmaceutical composition may be an enteral or a parenteral dosage form, suitable for transdermal, transmucosal, nasopharyngeal, pulmonary or direct injection, or for systemic (e.g., parenteral) or local (e.g., intratumor or intralesional injection) administration. Parenteral injection may be via intravenous (i.v.), intraperitoneal (i.p.), intramuscular (i.m.), subcutaneous (s.c.) or intradermal (i.d.) routes.
The pharmaceutical composition may also be administered orally, e.g., in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules.
The dosage of the fusion protein may vary, depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration. The dosage may be fitted to individual requirements in each particular case so as to obtain a therapeutically effective amount of the fusion protein of the invention to achieve a desired therapeutic response.
For adult patients receiving the fusion protein provided herein, a single dosage of about 0.1 to 50 mg, especially about 0.1 to 5 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile, the fusion protein may be administered with one dosage unit per week, bi-week or month, and totally give 1 to 6 dosage units per cycle to satisfy such treatment.
The invention relates to a combination or a pharmaceutical composition and use thereof for eliciting an antigen-specific cell-mediated immune response, treating a tumor, or a disease caused by a pathogen in a subject in need thereof.
The invention further relates to use of a combination or a pharmaceutical composition in the manufacture of a medicament for eliciting an antigen-specific cell-mediated immune response, treating a tumor or a disease caused by a pathogen in a subject in need thereof. The invention also relates to use of an immune checkpoint antibody in combination with use of a fusion protein defined above in the manufacture of medicament(s) for eliciting an antigen-specific cell-mediated immune response.
Alternatively, the invention relates to a method for eliciting an antigen-specific cell-mediated immune response in a subject in need thereof, comprising administering an effective amount of the combination or the pharmaceutical composition of the invention to the subject in need thereof.
A combination or a composition of the invention is useful for treating a tumor or an abnormal cell proliferation, or a disease caused by a pathogen in a subject in need thereof. The abnormal cell proliferation may be a pre-cancerous lesion or a tumor.
To administer a combination or a composition comprising an immune checkpoint antibody and a fusion protein, the antibody and the fusion protein may be administered to a patient simultaneously in the form of a single entity or dosage or administered to a patient as separate entities either simultaneously or sequentially. Such administration provides therapeutically effective amounts of active ingredients to the patient. For example, a fusion protein in a dose of between about 0.01 mg/kg, 0.02 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.075 mg/kg, 0.1 mg/kg, 0.125 mg/kg. 0.15 mg/kg, 0.175 mg/kg, 0.2 mg/kg, 0.225 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 0.75 mg/kg, 1 mg/kg, 1.25 mg/kg, 1.5 mg/kg, 1.75 mg/kg, 2 mg/kg, 2.25 mg/kg, 2.5 mg/kg, 2.75 mg/kg, 3 mg/kg, 3.25 mg/kg, 3.5 mg/kg, 3.75 mg/kg, 4 mg/kg, 4.25 mg/kg, 4.5 mg/kg, 4.75 mg/kg, to about 5 mg/kg all inclusive, twice daily, once daily, once every two, three, four, five or six days, or once, twice, or three times per week.
In another aspect, the invention provides kits containing the therapeutic combinations and directions for use thereof.
Abbreviations: MCS, multiple cloning sites; anti-PD-1, anti-programmed cell death-1; anti-PD-L1, anti-programmed cell death ligand-1; Rap1, Ras-proximate-1 or Ras-related protein J; CD40, Cluster of differentiation 40; CDR, Complementarity-determining region.
Table 1 shows SEQ ID numbers of corresponding peptides, polypeptides and fusion proteins.
Flow cytometry. Splenocytes were stimulated with an antigenic stimulator for 2 hours at 37° C., followed by treating with 50 μg/mL of Brefeldin A and Monensin at 37° C. for 2 hours. The cells were harvested, washed with PBS containing 0.5% BSA, and stained with APC/Cy7-conjugated anti-CD3 antibody, PerCP/Cy5.5-conjugated anti-CD4 antibody, FITC-conjugated anti-CD8 antibody, PE-conjugated anti-CD44 antibody and APC-conjugated anti-CD62L antibody simultaneously. After wash, the cells were permeabilized, fixed and intracellularly stained with PE-conjugated anti-IFN-γ antibody, PE/Cy7-conjugated anti-IL-2 antibody and eFluor450-conjugated anti-TNF-α antibody simultaneously. The intracellular cytokine characterization (IFN-γ, IL-2 or TNF-α) of splenocytes with CD8+ or CD4+ memory T cell phenotypes (CD3+/CD44hiCD62Lo) were further analyzed by Gallios flow cytometer and Kaluza software.
Enzyme-linked immunospot (ELISpot) assay. Splenocytes were seeded in triplicate in a pretreated murine IFN-γ capturing 96-well plate (CTL IMMUNOSPOT) at a cell density of 2×105 cells/well in the presence or absence of an antigenic stimulator. The cells were discarded after 24 hours of incubation at 37° C. After wash, the captured IFN-γ was detected by biotin-conjugated anti-murine IFN-γ antibody at room temperature for 2 hours and the IFN-γ-immunospots were developed according to the manufacturer's instructions. The scanning and counting of IFN-γ-immunospots was performed by IMMUNOSPOT® S5 Micro analyzer (CTL).
Indirect enzyme-linked immunosorbent assay (ELISA). Collected whole blood samples were left undisturbed at 4° C. for 30-60 minutes followed by centrifugation at 5,000 g for 10 minutes to pellet the clot. The serum samples were stored at −20° C. The purified coating protein for antigen-specific antibody binding was diluted in guanidine coating buffer (2 M guanidine hydrochloride, 500 mM Na2HPO4, 25 mM citrate, pH 4.0-4.4) and distributed into 96-well plate at 1 μg/well. After overnight incubation at 4° C., the 96-well plate was blocked with 1% BSA in PBS at 37° C. for 1 hour. The serum samples were thawed, and subsequently 10-fold serial diluted in PBS with 1% BSA. The coated protein was incubated with 100 μl of 1000-fold diluted serum sample at 37° C. for 2 hours. After 4 times washing with phosphate buffered saline TWEEN®-20 (PBST), the antigen-specific antibodies were detected by horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (at a dilution of 1:10,000, Cat #31430, Thermo Fisher Science) at 37° C. for 30 minutes. Following 4 times of washing with PBST, the HRP-mediated color development was catalyzed in the presence of 100 μL of TMB substrate and quenched by 100 μL of 1 N HCl. The relative titers of antigen-specific antibody in the serum samples were determined by the absorbance at 450 nm.
Statistical analysis. Using a t-test, results considered significant when p<0.05.
CD40L47-261-TPE-E7 and 18sCD40L-TPE-E7. The vector CD40L47-261-TPE-E7 (
Using a similar method described above, any other antigen(s) of interest may replace E7 and be inserted into the plasmid of
Similarly, an expression vector for generating 18sCD40L-TPE-E7 fusion protein (SEQ ID NO: 52;
E7-TStx-CD40L47-261 and E7-TStx-18sCD40L. The vector E7-TStx-CD40L47-261 (
Briefly, a DNA fragment encoding HindIII,XhoIStx-Linker-CD40LSalI, which comprises a Stx translocation peptide (Stx211-247), a cleavable linker and CD40L47-261, was PCR synthesized, digested by HindIII/Sa/I, ligated into the plasmid pTAC-MAT-Tag-2 having HindIII/XhoI cutting sites to obtain the plasmid P08(RP)-His-pNC (
The cleavable linker is vital because it allows the fusion protein of the invention to be cut by furin and/or cathepsin L protease inside a cell and release the E7-TStx fragment (
Any other antigen(s) of interest from various pathogen or cancer origins may replace E7 and be inserted into the plasmid of
Similarly, an expression vector for generating E7-TStx-18sCD40L fusion protein (SEQ ID NO: 54;
For a comparison purpose, RAP1-CD28convPEt-E7-K3 fusion protein (named as “RAP1-E7”) was constructed. It comprised a RAP1 domain III, a CD28 sequence, a linker, a PE translocation domain II (PE268-313), an antigen E7 protein and an endoplasmic reticulum retention sequence, in which the antigen E7 protein was a fusion antigen (HPV16/18 E7) comprising an HPV16 E7 protein (SEQ ID NO: 38) and an HPV18 E7 protein (SEQ ID NO: 39). This “RAP1-E7” fusion protein was almost identical to a prior construct disclosed in the U.S. Pat. No. 9,481,714 B2, Example 1, with the only difference in that the antigen E7 protein disclosed in the prior art was HPV16 E7 protein, rather than an HPV16/18 E7 fusion antigen.
HBx-preS1-TStx-18sCD40L. The vector HBx-preS1-TStx-18sCD40L was constructed to generate HBx-preS1-TStx-18sCD40L fusion protein (SEQ ID NO: 55;
The vector HBx-preS1-TStx-18sCD40L was constructed using a similar method as aforementioned, in which the truncated CD40 ligand was replaced by CD40L108-261 and the fusion antigen was replaced by HBx-preS1.
E. coli BL21 cells harboring expression vectors were grown in ZY media (10 g/L tryptone and 5 g/L yeast extract) containing selection antibiotics at 37° C. When the culture reached an early log phase (OD600=2 to 5), the expression of fusion protein was induced by isopropyl-1-thio-β-D-galactopyranoside (IPTG) (0.5 to 2 mM). Cells were harvested after 4 hours of IPTG induction and disrupted by sonication. The inclusion bodies were isolated and solubilized in solubilization buffer (6 M guanidine hydrochloride, 20 mM potassium phosphate, 500 mM NaCl, 20 mM imidazole, 1 mM DTT, pH 7.4) to recover overexpressed fusion proteins. After purification, the refolding of the fusion proteins was performed by dialysis against 20- to 50-fold volume of dialysis buffer (10 mM PBS) at 4° C. overnight. The refolded fusion proteins were subject to SDS-PAGE analyses under reduced (with dithiothreitol; +DTT) and non-reduced (without dithiothreitol; −DTT) conditions to evaluate whether they were properly refolded.
The fusion proteins CD40L47-261-TPE-E7, 18sCD40L-TPE-E7, E7-TStx-18sCD40L and RAP1-E7 purified were further subjected to immunogenicity analyses to evaluate their biological activities.
Female C57BL/6NCrlBltw mice (5 to 6-week-old) were randomly divided into 5 groups (n=5): (A) placebo (i.e., PBS); (B) CD40L47-261-TPE-E7 (100 μg) fusion protein; (C) 18sCD40L-TPE-E7 (100 μg) fusion protein; (D) E7-TStx-18sCD40L (100 μg) fusion protein; and (E) RAP1-E7 (100 μg) fusion protein. The fusion proteins were dialyzed into PBS. CpG1826 (50 μg) was used as an adjuvant in animal groups B to E. Each group received three immunizations subcutaneously (s.c.) at 7 day intervals from day 0. Blood samples were collected on day 0, 7 and 14. On day 21, the blood samples were harvested and the splenocytes were resuspended in RPMI 1640 medium containing FBS (10%) and PSA.
The splenocytes were used to analyze intracellular cytokine induction (IFN-γ, IL-2 and TNF-α) in the CD8 and CD4 memory T cells in the presence and absence of antigen stimulation. Briefly, splenocytes from each animal group were treated with or without antigen E7 protein (2 μg/mL of HPV16 E7 peptide pool) and then analyzed by flow cytometry. The degree or the level of the intracellular cytokine induction in each mouse group was presented as a relative cytokine induction, which was obtained by normalizing the frequency of cytokine/CD8 and cytokine/CD4 splenocytes in the presence of the stimulating antigen E7 to that of the unstimulated (untreated) control.
The splenocytes were also used to analyze the frequency of IFN-γ-secreting splenocytes in the presence and absence of antigen stimulation (2 μg/mL of HPV16 E7 peptide pool) by using Enzyme-linked immunospot (ELISpot) assay. The results were presented as IFN-γ+ immunospots per million splenocytes.
The blood samples were used to analyze the level of serum HPV16 E7-specific and HPV18 E7-specific antibody by using ELISA, in which the purified HPV16 E7 and HPV18 E7 recombinant proteins were used as coating proteins, respectively.
It was concluded that the fusion protein of the invention was superior to the prior art fusion protein in inducing IFN-γ and TNF-α secretions in CD8 memory T cells in response to the stimulation of the antigen HPV16 E7.
The results indicated that the fusion proteins of the invention could significantly increase IFN-γ-secreting T cell population upon or after stimulation with the antigenic HPV16 E7 peptide pool.
RAP1-E7 (RAP1-CD28convPEt-E7-K3) fusion protein failed to elicit HPV16 E7-specific antibody level after two vaccinations (on day 0 and 7). It started to induce serum HPV16 E7-specific antibody after the third vaccination on day 14, and the serum antibody level was only modest on day 21 as compared to animals treated with the aforementioned fusion proteins of the invention. A similar pattern was also observed in inducing HBx-specific antibody when animals were vaccinated with RAP1-CD28convPEt-HBx-K3 (referred to as “RAP1-HBx”), using the same regimen and immunization schedule described above. The fusion protein RAP1-HBx was generated by using HBx antigen to replace the E7 antigen in the RAP1-E7. The fusion protein RAP1-HBx induced serum HBx-specific antibody level after the third vaccination on day 14, and the serum antibody level on day 21 was only modest (data not shown).
In contrast, the fusion protein of the invention elicited serum HPV16 E7-specific antibody level after two shots of the vaccines on day 0 and 7 (
Thus, the fusion proteins of the invention were effective in inducing antigen-specific antibodies and the antibody induction occurred after twice vaccinations.
In summary, the antigen-carrying fusion proteins of the invention could effectively induce antigen-specific T cell response, increase the expression of proinflammatory cytokines, e.g., IFN-γ and TNF-α, and generate antigen-specific antibody response.
Fusion Proteins in Combination with an Immune Checkpoint Inhibitor in a Mouse Model of HPV Infection
CD40L47-261-TPE-E7, 18sCD40L-TPE-E7, and E7-TStx-18sCD40L fusion proteins were each combined with an immune checkpoint inhibitor antibody (an anti-PD-1 antibody), and each combination was tested for efficacy in a mouse HPV 16 tumor model.
Female C57BL/6NCrlBltw mice (5 to 6-week-old) were randomly divided into 5 groups: (A) placebo (PBS, n=4); (B) anti-PD-1 antibody (100 μg; catalog no. BE0146, Bio X Cell, Inc.) in combination with CD40L+7-261-TPE-E7 (25 μg) (n=5); (C) anti-PD-1 antibody (100 μg) in combination with 18sCD40L-TPE-E7 (25 μg) (n=4); (D) anti-PD-1 antibody (100 μg) in combination with E7-TStx-18sCD40L (25 μg) (n=5); and (E) anti-PD-1 antibody alone (100 μg) (n=5). In Groups B to D, the fusion proteins were dissolved in PBS and CpG1826 (50 μg) was used as an adjuvant in immunizing animals.
An HPV16 E6- and E7-expressing tumor cell line (TC-01) from lung epithelial cells of C57BL/6 mice was used to establish a mouse HPV 16 tumor model. Tumor cells were grown in RPMI 1640 medium containing FBS (10%) and penicillin/streptomycin/Amphotericin B (50 units/mL) at 37° C., 5% CO2. To challenge mice, tumor cells (1×105 in 0.1 mL) were injected subcutaneously into the left flank of each mouse on day 0. Mice in each group received three doses of test articles (i.e., placebo, anti-PD-l antibody, or an combination therapy) on days 7, 14 and 21. In each dosing, the fusion protein was given subcutaneously, and the anti-PD-1 antibody was given intraperitoneally. All survived mice were sacrificed on day 39.
The tumor size was determined twice a week by multiplication of caliper measurements based on the modified ellipsoidal formula: Tumor volume=1/2 (length×width2). The survival rate and tumor free rate were calculated. Mice with tumor length over 2 cm were considered dead and mice without measurable or palpable tumor masses were considered tumor-free. The significance of each comparison was calculated by using t-test, and results considered significant when p<0.05.
The inoculated tumor developed rapidly in the placebo group, in which two animals died on day 25 and thus the data for the placebo group were shown only until day 21 (
The animal groups receiving anti-PD-1 antibody in combination with 18sCD40L-TPE-E7, and E7-TStk-18sCD40L, respectively, remained 100% survival rate on day 39, and the group receiving anti-PD-1 antibody in combination with CD40L47-261-TPE-E7 kept at 80% survival rate on day 39, while in the placebo group all mice died on day 35, and the group receiving PD-1 only declined to 20% survival rate on day 35 (
No tumor-free animals could be found in the placebo and PD-1 only groups during the entire experimental period (day 39) (
E7-TStx-18sCD40L Fusion Protein in Combination with an Immune Checkpoint Stimulator in a Mouse Model of HPV Infection
E7-TStx-18sCD40L fusion protein in combination with an immune checkpoint stimulator antibody (an anti-CD137 antibody) was tested in a mouse HPV 16 tumor model, which was established as described above.
The animal grouping and immunization schedule were shown in Table 2. Female C57BL/6NCrlBltw mice (5 to 6-week-old) were randomly divided into 4 groups (n=5 each group): (1) Group A (placebo; PBS); (2) Group B (E7-TStx-18sCD40L); (3) Group C (anti-CD137 antibody; catalog no. BE0239, Bio X Cell, Inc.); and (4) Group D (E7-TStx-18sCD40L in combination with anti-CD137 antibody).
To challenge mice, the HPV tumor cells having a higher concentration of 1×106 in 0.1 mL were inoculated subcutaneously into the left flank of each mouse on day 0. In placebo group, PBS was given on Day 14 and 21. For each vaccination (Table 2), the fusion protein E7-TStx-18sCD40L was dissolved in PBS, adjuvanted with CpG1826 (50 μg/dose) and then given subcutaneously. The anti-CD137 antibody was given intraperitoneally. All mice were sacrificed on day 41.
The tumor developed rapidly in the placebo and anti-CD137 antibody only groups, all the mice died around Day 30, which caused no more data could be recorded any further. Surprisingly, the anti-CD137 antibody alone was found making no contribution to tumor suppression here (
The tumor mass in the group receiving E7-TStx-18sCD40L only was well controlled initially, started to grow slowly 7 days after the 2nd immunization. Notably, the tumor suppression effect of the fusion protein was maintained for at least one week after the last immunization even though only two vaccinations were administered and a higher amount of tumor cells were inoculated (ten times of the amount used in the aforementioned PD-1 combination study).
The tumor mass in the group receiving E7-TStk-18sCD40L in combination with anti-CD137 antibody was suppressed and found continuous tumor shrinkage until the end of the experiment on day 42. It could be reasonably speculated that the tumor mass might be able to be cleared completely given a longer observation period. Unexpectedly, the anti-CD137 antibody showed a synergistic effect to the fusion protein E7-TStx-18sCD40L. The results indicated that the combination of the invention could effectively suppress tumor growth.
The group receiving combination of E7-TStk-18sCD40L with anti-CD137 antibody remained 100% survival rate until the last observation day, while the group receiving E7-TStx-18sCD40L declined to 40% survival rate, and both placebo and anti-CD137 antibody only groups declined to 0% survival rate (
Accordingly, a combination of an E7-carrying fusion protein with an immune checkpoint antibody capable of activating T cell, such as an anti-PD-1 antagonist antibody, or an anti-CD137 agonist antibody, could exhibit an excellent tumor suppression effect and be used for treating tumors or abnormal cell proliferation.
Efficacy Analyses: HBx-preS1-TStx-18sCD40L Fusion Protein in Combination with an Immune Checkpoint Antibody in a Mouse Model of HBV Infection
A combination of HBx-preS1-TStx-18sCD40L with an immune checkpoint inhibitor (an anti-PD-1 antibody) or an immune checkpoint stimulator (an anti-CD137 antibody) is tested for the efficacy in a HBV-infection mouse model.
Mice are divided into several groups: control (PBS), vaccine (HBx-preS1-TStx-18sCD40L), PD-1 (anti-PD-1 antibody), CD137 (anti-CD137 antibody), PD-1 combo (anti-PD-1 antibody and HBx-preS1-TStx-18sCD40L), and CD137 combo groups (anti-CD137 antibody and HBx-preS1-TStx-18sCD40). The fusion protein is adjuvanted with CpG1826 and given subcutaneously. Antibodies were given intraperitoneally.
A HBV-infection mouse model is an AAV-HBV mouse model described in U.S. Pat. No. 10,058,606 B2 and can be suitably modified if needed. Briefly, male mice (5-6 weeks old) are used to establish an animal model carrying a long-term hepatitis B virus. A mixture of pAAV/HBV1.2 plasmid and saline is intravenously injected into the mouse tail vein at a high pressure (hydrodynamic injection, HDI) in a fast mode to force the plasmid to penetrate the cell membrane and enter liver cells. The plasmid-carrying liver cells express hepatitis B virus proteins. Virus will assemble inside the liver cells and release into blood. This animal model emulates a human patient afflicted with chronic hepatitis B symptoms.
Twenty-eight days after the high-pressure injection, mice in each group receive three doses of fusion proteins and/or indicated antibodies on Days 0, 7, 14 with a 7 day interval. The body weights are measured on the same day of high-pressure injection, and on Day 0, 7, 14, 21, 32, and 42. Blood is collected for analyses of alanine aminotransferase (ALT), bilirubin, viral DNA, and surface antigen (HBsAg). Mice are sacrificed 82 days after the first vaccination, and liver core antigen (HBcAg) quantity is analyzed.
The administration of HBx-preS1-TStx-18sCD40 in combination with an anti-PD-1 antibody or an anti-CD137 antibody is expected to exhibit an outstanding therapeutic effect on HBV infection. For example, said combination is expected to reduce viral DNA load, HBsAg and HBcAg, and induce an HBx-specific immune response. Use of said combination (i.e., the HBx-carrying fusion protein combined with an immune checkpoint modulator) is expected to effectively inhibit the proliferation of hepatitis B virus in liver cells and suppress hepatitis B virus infection in HBV patients.
In summary, the novel antigen-carrying fusion proteins can elicit a potent antigen-specific T cell immune response due to its unique protein design and mechanism of action. An immune checkpoint modulator is able to restore T cell function by antagonizing an inhibitory immune checkpoint (e.g., PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIGIT, CD96, CD122R, TIM3, VISTA, CEACAMI, SIGLEC-7, SIGLEC-9, SIGLEC-15, KIRi, CD200R, BTLA, and ILT2) or activate T cell by agonizing a stimulatory immune checkpoint (e.g., CD137, OX40, GITR, ICOS, CD27, CD28, CD40, 5 KIRs, CD226 and CD244). When at least one suitable antigen is applied in the fusion protein and a suitable immune checkpoint modulator is selected, both of which contribute to upgrade T cell immunity and could achieve a great therapeutic efficacy when they are used in combination. Therefore, the invention provides an original inventive conception of using the combinations that are not disclosed in any prior publications for treating tumors and infectious diseases.
All references cited and discussed in this specification are incorporated herein by reference in their entireties and to the same extent as if each reference was individually incorporated by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2022/076636 | 9/19/2022 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63271982 | Oct 2021 | US |
